Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | BCL2L1 | Q07817 | 4/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.52 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL680289 | 0.85 | MCL1 (0.70) | BCL2L1MCL1SCN3ASCN9ARAB9A | |
| SCHEMBL679956 | 0.82 | MAPK14 (0.55) | BCL2L1MCL1SCN3ASCN9AMEN1 | |
| SCHEMBL679939 | 0.82 | MEN1 (0.60) | BCL2L1MCL1SCN3ASCN9AMEN1 | |
| SCHEMBL680159 | 0.81 | CXCL8 (0.59) | BCL2L1MCL1SCN3ASCN9A | |
| SCHEMBL680618 | 0.81 | MAPK14 (0.54) | SCN3ASCN9AMEN1KMT2A | |
| SCHEMBL16319656 | 0.80 | SCN9A (0.44) | BCL2L1MCL1SCN3ASCN9AMEN1 | |
| SCHEMBL680339 | 0.79 | KMT2A (0.51) | BCL2L1MCL1SCN3ASCN9AMEN1 | |
| SCHEMBL679785 | 0.79 | MCL1 (0.62) | BCL2L1MCL1SCN3ASCN9AFFAR4 | |
| SCHEMBL680203 | 0.79 | SCN3A (0.45) | BCL2L1MCL1SCN3ASCN9AMEN1 | |
| SCHEMBL680509 | 0.79 | SCN3A (0.50) | BCL2L1MCL1SCN3ASCN9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593427-B1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | PFIZER LTD (GB) | 2014-12-24 | — | — | EP | disclosed |
| US-20120010207-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010207-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | PTGS2 2357/4885BCL2L1 3284/4885MCL1 2739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.